Notification of a Public Teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission), 26813 [2017-12023]
Download as PDF
Federal Register / Vol. 82, No. 110 / Friday, June 9, 2017 / Notices
community response to the new,
quieter, sonic booms.
II. Method of Collection
Telephone.
III. Data
Title: Pilot Testing of Telephone
Interviewing Approaches to Assess
Community Response to New, Quieter
Boom Experiences.
OMB Number: 2700–XXXX.
Type of review: New information
collection.
Affected Public: Individuals.
Estimated Number of Respondents:
5,000.
Estimated Time per Response: 3
minutes.
Estimated Total Annual Burden
Hours: 250.
Estimated Total Annual Cost to
Respondents: $0.
IV. Request for Comments
Comments are invited on: (1) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of NASA, including
whether the information collected has
practical utility; (2) the accuracy of
NASA’s estimate of the burden
(including hours and cost) of the
proposed collection of information; (3)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) ways to minimize the
burden of the collection of information
on respondents, including automated
collection techniques or the use of other
forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the request for OMB
approval of this information collection.
They will also become a matter of
public record.
Frances Teel,
NASA PRA Clearance Officer.
[FR Doc. 2017–12000 Filed 6–8–17; 8:45 am]
BILLING CODE 7510–13–P
OFFICE OF NATIONAL DRUG
CONTROL POLICY
mstockstill on DSK30JT082PROD with NOTICES
Notification of a Public Teleconference
of the President’s Commission on
Combating Drug Addiction and the
Opioid Crisis (Commission)
Office of National Drug Control
Policy (ONDCP).
ACTION: Notice of teleconference.
AGENCY:
ONDCP announces a meeting
by teleconference of the President’s
Commission on Combating Drug
Addiction and the Opioid Crisis. The
SUMMARY:
VerDate Sep<11>2014
19:25 Jun 08, 2017
Jkt 241001
purpose of the meeting is to review a
draft interim report that will be posted
on ONDCP’s Commission Web site
listed below before the teleconference.
DATES: The teleconference will be held
on Monday June 26, 2017 at 4:00 p.m.
(Eastern time).
ADDRESSES: There will be no physical
address. The public may call (866) 233–
3841 (Access Code 425352) to listen.
Please call five minutes before the start
time. If you are part of an organization,
please try to consolidate use to as few
lines as possible.
FOR FURTHER INFORMATION CONTACT:
General information concerning the
Commission and its meetings can be
found on ONDCP’s Web site at https://
www.whitehouse.gov/ondcp/presidentscommission. Any member of the public
wishing to obtain information about the
Commission or its meetings that is not
already on ONDCP’s Web site or who
wishes to submit written comments for
the Commission’s consideration may
contact Michael Passante, Designated
Federal Officer (DFO) via email at
commission@ondcp.eop.gov or
telephone at (202) 395–6709. Please
note that ONDCP may post such written
comments publicly on our Web site,
including names and contact
information that are submitted. There
will not be oral comments from the
public on the teleconference. Requests
to accommodate disabilities should also
be sent to that email address, preferably
at least 10 days prior to the meeting to
allow time for processing.
SUPPLEMENTARY INFORMATION: The
Commission was established in
accordance with E.O. 13784 of March
29, 2017, the Commission’s charter, and
the provisions of the Federal Advisory
Committee Act (FACA), as amended, 5
U.S.C. App. 2, to obtain advice and
recommendations for the President
regarding drug issues. The Executive
Order, charter, and information on the
Members of the Commission are
available on ONDCP’s Web site. The
Commission will function solely as an
advisory body and will make
recommendations regarding policies
and practices for combating drug
addiction with particular focus on the
current opioid crisis in the United
States. The Commission’s final report is
due October 1, 2017 unless there is an
extension. Per E.O. 13784, the
Commission shall:
a. Identify and describe the existing
Federal funding used to combat drug
addiction and the opioid crisis;
b. assess the availability and
accessibility of drug addiction treatment
services and overdose reversal
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
26813
throughout the country and identify
areas that are underserved;
c. identify and report on best practices
for addiction prevention, including
healthcare provider education and
evaluation of prescription practices,
collaboration between State and Federal
officials, and the use and effectiveness
of State prescription drug monitoring
programs;
d. review the literature evaluating the
effectiveness of educational messages
for youth and adults with respect to
prescription and illicit opioids;
e. identify and evaluate existing
Federal programs to prevent and treat
drug addiction for their scope and
effectiveness, and make
recommendations for improving these
programs; and;
f. make recommendations to the
President for improving the Federal
response to drug addiction and the
opioid crisis.
Dated: June 6, 2017.
Michael Passante,
Acting General Counsel, Designated Federal
Officer.
[FR Doc. 2017–12023 Filed 6–8–17; 8:45 am]
BILLING CODE 3280–F5–P
NATIONAL SCIENCE FOUNDATION
Sunshine Act Meeting; National
Science Board
The National Science Board’s
Committee on Awards and Facilities
(A&F), pursuant to NSF regulations (45
CFR part 614), the National Science
Foundation Act, as amended (42 U.S.C.
1862n–5), and the Government in the
Sunshine Act (5 U.S.C. 552b), hereby
gives notice of the scheduling of a
teleconference for the transaction of
National Science Board business, as
follows:
DATES AND TIME: Friday, June 16, 2017
from 11:00 a.m.–12:00 p.m. EDT.
SUBJECT MATTER: Committee Chair’s
opening remarks; discussion of
Information-Action Item Sequence; the
Lead Reviewer Guide; the Portfolio
Level Information in Facility Portal; and
Committee Chair’s closing remarks.
STATUS: Open.
LOCATION: This meeting will be held by
teleconference at the National Science
Foundation, 4201 Wilson Blvd.,
Arlington, VA 22230. An audio link will
be available for the public. Members of
the public must contact the Board Office
to request the public audio link by
sending an email to
nationalsciencebrd@nsf.gov at least 24
hours prior to the teleconference.
E:\FR\FM\09JNN1.SGM
09JNN1
Agencies
[Federal Register Volume 82, Number 110 (Friday, June 9, 2017)]
[Notices]
[Page 26813]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12023]
=======================================================================
-----------------------------------------------------------------------
OFFICE OF NATIONAL DRUG CONTROL POLICY
Notification of a Public Teleconference of the President's
Commission on Combating Drug Addiction and the Opioid Crisis
(Commission)
AGENCY: Office of National Drug Control Policy (ONDCP).
ACTION: Notice of teleconference.
-----------------------------------------------------------------------
SUMMARY: ONDCP announces a meeting by teleconference of the President's
Commission on Combating Drug Addiction and the Opioid Crisis. The
purpose of the meeting is to review a draft interim report that will be
posted on ONDCP's Commission Web site listed below before the
teleconference.
DATES: The teleconference will be held on Monday June 26, 2017 at 4:00
p.m. (Eastern time).
ADDRESSES: There will be no physical address. The public may call (866)
233-3841 (Access Code 425352) to listen. Please call five minutes
before the start time. If you are part of an organization, please try
to consolidate use to as few lines as possible.
FOR FURTHER INFORMATION CONTACT: General information concerning the
Commission and its meetings can be found on ONDCP's Web site at https://www.whitehouse.gov/ondcp/presidents-commission. Any member of the
public wishing to obtain information about the Commission or its
meetings that is not already on ONDCP's Web site or who wishes to
submit written comments for the Commission's consideration may contact
Michael Passante, Designated Federal Officer (DFO) via email at
commission@ondcp.eop.gov or telephone at (202) 395-6709. Please note
that ONDCP may post such written comments publicly on our Web site,
including names and contact information that are submitted. There will
not be oral comments from the public on the teleconference. Requests to
accommodate disabilities should also be sent to that email address,
preferably at least 10 days prior to the meeting to allow time for
processing.
SUPPLEMENTARY INFORMATION: The Commission was established in accordance
with E.O. 13784 of March 29, 2017, the Commission's charter, and the
provisions of the Federal Advisory Committee Act (FACA), as amended, 5
U.S.C. App. 2, to obtain advice and recommendations for the President
regarding drug issues. The Executive Order, charter, and information on
the Members of the Commission are available on ONDCP's Web site. The
Commission will function solely as an advisory body and will make
recommendations regarding policies and practices for combating drug
addiction with particular focus on the current opioid crisis in the
United States. The Commission's final report is due October 1, 2017
unless there is an extension. Per E.O. 13784, the Commission shall:
a. Identify and describe the existing Federal funding used to
combat drug addiction and the opioid crisis;
b. assess the availability and accessibility of drug addiction
treatment services and overdose reversal throughout the country and
identify areas that are underserved;
c. identify and report on best practices for addiction prevention,
including healthcare provider education and evaluation of prescription
practices, collaboration between State and Federal officials, and the
use and effectiveness of State prescription drug monitoring programs;
d. review the literature evaluating the effectiveness of
educational messages for youth and adults with respect to prescription
and illicit opioids;
e. identify and evaluate existing Federal programs to prevent and
treat drug addiction for their scope and effectiveness, and make
recommendations for improving these programs; and;
f. make recommendations to the President for improving the Federal
response to drug addiction and the opioid crisis.
Dated: June 6, 2017.
Michael Passante,
Acting General Counsel, Designated Federal Officer.
[FR Doc. 2017-12023 Filed 6-8-17; 8:45 am]
BILLING CODE 3280-F5-P